FDA Approves Decnupaz, First CD123-Directed Therapy for Rare Blood Cancer
The FDA has granted approval to Decnupaz, a novel antibody-drug conjugate targeting blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive blood cancer. The approval represents a significant advance for patients with this previously difficult-to-treat malignancy.
Approval Details
Decnupaz (pivekimab sunirine-pvzy) is a CD123-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm, approved by the FDA on May 27, 2026.
What Is Blastic Plasmacytoid Dendritic Cell Neoplasm?
Blastic plasmacytoid dendritic cell neoplasm is a rare hematologic malignancy characterized by rapid proliferation of abnormal dendritic cells. The disease is highly aggressive, often presents at advanced stages, and historically has carried a poor prognosis with limited treatment options. Median survival is typically measured in months without effective therapy.
Significance of the Approval
Decnupaz represents a targeted approach to treating this cancer by leveraging CD123, a surface marker expressed on abnormal plasmacytoid dendritic cells. The antibody-drug conjugate design allows precise delivery of cytotoxic chemotherapy directly to cancer cells while minimizing exposure to healthy tissues. This targeted mechanism offers potential benefits in terms of efficacy and reduced side effects compared to conventional chemotherapy.
Broader Treatment Pipeline
Hepcludex (bulevirtide-gmod), a novel virion entry inhibitor for the treatment of adults with chronic hepatitis delta virus infection, received FDA accelerated approval on May 22, 2026. Baxfendy (baxdrostat), a first-in-class, highly selective aldosterone synthase inhibitor for use in the treatment of hypertension, received FDA approval on May 18, 2026. The recent FDA approvals demonstrate continued progress in developing targeted therapies for both rare cancers and common chronic diseases.